【摘要】 目的 探討中晚期宮頸癌術前動脈灌注化療栓塞的臨床價值。 方法 選擇2005年6月-2009年12月35例經陰道鏡活檢確診為宮頸癌臨床分期Ⅱa~Ⅲb期宮頸癌患者，術前行1次子宮動脈化療栓塞，化療藥物為博萊霉素（BLM）+順鉑（DDP）+環磷酰胺（CTX），栓塞劑為超液化碘油加明膠海綿顆粒。介入治療后14~20 d行子宮全切加淋巴結清掃術。觀察動脈灌注化療栓塞前后腫塊的大小變化、術中腫塊粘連狀況及出血量的多少。 結果 經介入治療后腫塊縮小32例：完全緩解（CR）3例、部分緩解（PR）29例，腫塊無變化（NC）2例，進展（PD）1例，治療有效率為91.4%。31例選擇了手術治療，手術率為88.6%。術中腫塊粘連狀況：無粘連24例，輕度粘連6例，中度粘連1例。術中出血量：≤100 mL 7例，100~200 mL 18例，200~400 mL 6例。 結論 中晚期宮頸癌術前動脈灌注化療栓塞能有效地提高腫瘤切除率，降低手術風險。【Abstract】 Objective To evaluate the clinical value of preoperative transarterial chemoembolization for advanced cervical cancer. Methods A total of 35 patients with pathologically proved cervical cancer (from stage Ⅱa to Ⅲb) from June 2005 to December 2009 received preoperative transarterial chemoembolization once. Bleomycin, cisplantin and cytoxan were infused via bilateral uterine arteries, followed by arterial emboliezation with super-liquefaction iodipin and gel foam particles as embolic agent. Radical surgery was performed on the patients after 14-20 days. Volume change of mass, accretion state and haemorrhagia amount during the operation were analyzed. Results The masses deflated in 32 cases: complete response (CR) in 3, and partial response (PR) in 29. No change (NC) was seen in 3 cases. The effective rate was 91.4%. In 31 cases who underwent the operation, the operability was 88.6%, in whom non-accretionin was in 24, light accretion was in 6 and medium accretion was in 1. Haemorrhagia amount was less than 100 mL in 11 cases, 100-200 mL in 21cases, and 200-1 400 mL in 3 cases. Conclusion Preoperative chemoembolization can elevate exairesis rate and depress the operative risk effectively.
摘要:目的: 評估手術、栓塞及γ刀綜合治療腦動靜脈畸形的療效。 方法 :回顧性分析了我科自2002年3月至2009年7月期間綜合治療的43例腦AVM患者,分析評估這43例腦AVM的臨床特點及治療效果,隨訪患者并對其進行GOS評分。 結果 :本組病例采取栓塞＋手術治療3例、栓塞＋γ刀治療26例、手術＋γ刀治療11例、栓塞+手術＋γ刀治療3例。術后隨訪28例,隨訪時間4月至7年6月,GOS評分5分者25例,患者均能重新回到工作或學校;GOS評分4分者2例,患者生活能夠自理;GOS評分1分者1例,患者死亡。 結論 :對大型、功能區、有深部靜脈引流的腦AVM綜合治療有一定的優越性,它不僅使腦AVM治愈率明顯提高,而且與治療相關的各種并發癥和病死率也明顯降低。Abstract: Objective: To evaluate the efficacy of multimodality treatment of cerebral arteriovenous malformations(AVMs) with surgery, embolization and γknife radiation. Methods : A retrospective analysis of 43 cases of cerebral AVMs applied with multimodality treatment in our department From March 2002 to July 2009 has been made, meanwhile we have analyzed and assessed the clinical characteristics and treatment outcome of these 43 patients with cerebral AVMs. Results : Patients received multimodality treatment with embolization followed by surgery(n=3), embolization followed by γknife radiation(n=26), surgery followed by γknife radiation(n=11), or embolization, surgery, and γknife radiation(n=3). Postoperative followup of 28 cases, the followup time is 4 months to 7 years and 6 months. GOS score 5 in 25 cases, who can be able to return to work or school. GOS score 4 in 2 cases, who can be able to live independently. GOS score 1 in 1 case, who is dead. Conclusion : In the cerebral AVMs which are large, or located within or immediately adjacent to eloquent regions of the brain, or have deep venous drainage, multimodality treatment has some superiority. It can not only improve the cure rate of cerebral AVMs significantly, but also reduce the treatmentrelated complications and mortality.
Objective To explore the causal association between obstructive sleep apnea (OSA) and venous thromboembolism (VTE). Methods Using the summary statistical data from the FinnGen biological sample library and IEU OpenGWAS database, the relationship between OSA and VTE, including deep vein thrombosis (DVT) and pulmonary embolism, was explored through Mendelian randomization (MR) method, with inverse variance weighted (IVW) as the main analysis method. Results The results of univariate MR analysis using IVW method showed that OSA was associated with VTE and pulmonary embolism (P<0.05), with odds ratios and 95% confidence intervals of 1.204 (1.067, 1.351) and 1.352 (1.179, 1.544), respectively. There was no correlation with DVT (P>0.05). Multivariate MR analysis showed that after adjustment for confounding factors (smoking, diabetes, obesity and cancer), OSA was associated with VTE, DVT and pulmonary embolism (P<0.05), with odds ratios and 95% confidence intervals of 1.168 (1.053, 1.322), 1.247 (1.064, 1.491) and 1.158 (1.021, 1.326), respectively. Conclusion OSA increases the risk of VTE, DVT, and pulmonary embolism.
Objective To evaluate the safety and effectiveness of interventional therapy for hyperthyroidism. Methods From 1995 to 2000, 38 cases underwent bilateral super-selective superior thyroid arteries embolization with brown-algae microballs.Results There was no misembolization and mortality. Hyperthyroidism crisis developed in 2 cases. Thirty eight cases were followed-up for 0.5～5 years (the median time was 2.2 years). Medications were needed only in one patient because of relapse and the others were cured. Conclusion This procedure features miniinvasive trauma, less complications and quick recovery. It may be a safe and rational treatment for hyperthyroidism.
ObjectiveTo investigate the risk or protective factors for systemic embolism (SE) in patients undergoing bioprosthetic mitral valve replacement (MVR).
Methods Between October 2002 and March 2013, a total of 146 patients underwent bioprosthetic MVR. There were 78 females and 68 males with mean age of 66.23±5.17 years. The primary reason of mitral valve disease was mitral valve degeneration or mitral valve leaflet prolapse in 40 patients, rheumatic heart valve disease in 101 patients, ischemic heart disease in 3 patients, infectious endocarditis in 1 patient, and mechanical peri-valvular leak in 1 patient. All patients were given anticoagulation therapy with warfarin for 3 months. Thereafter, antithrombotic medication was prescribed according to the surgeon's preference. The patients were followed up by telephone or mail for postoperative condition and SE events.
ResultsSixteen (10.96%) patients developed SE events, including cerebral infarction in 13 cases, transient ischemic attack (TIA) in 2 cases and spleen infarction in 1 case. A total of 16 patients died during follow-up. The 1-year, 3-year, 5-year and 10-year cumulative survival rate after surgery was 95.2%, 93.6%, 92.5% and 88.3% respectively. Patients with SE events had lower rate of left atrial appendage obliteration than those without SE events (25.0% vs. 78.6%, P=0.015). Multivariate analysis showed that left atrial appendage obliteration was an independent protective factor for SE in patients undergoing bioprosthetic MVR (P=0.041).
ConclusionLeft atrial appendage obliteration is a major protective factor for systemic embolism in patients undergoing bioprosthetic MVR no matter what antithrombotic medication is taken.
